Identification of Prostate Cancer Subtypes Based on Immune Signature Scores in Bulk and Single Cell Transcriptomes

Canping Chen,Xiaosheng Wang

doi:10.2139/ssrn.3986700

Abstract

Identification of Prostate Cancer Subtypes Based on Immune Signature Scores in Bulk and Single Cell Transcriptomes

Highlights

Prostate cancer (PC) is the second most common cancer in men worldwide, with more than 1,275,000 new diagnoses and 350,000 deaths annually
We performed the clustering analysis in ten PC datasets (TCGA-PRAD, DKFZ2018, GSE21034, GSE46602, GSE54460, GSE70770, GSE107299, GSE116918, GSE141551, and GSE157547), respectively
We found that PC immunity high (PC-ImH) harbored a higher proportion of late-stage (T3-4) tumors than PC immunity low (PC-ImL) (P = 0.063; odds ratio (OR) = 1.43) (Fig. 2D)

Summary

Introduction

Prostate cancer (PC) is the second most common cancer in men worldwide, with more than 1,275,000 new diagnoses and 350,000 deaths annually. Abundant evidence has shown that PC is highly heterogeneous in genomic and phenotypic characteristics [1]. By analyzing 333 primary PCs, The Cancer Genome Atlas (TCGA) revealed that more than 70% of PCs belonged to one of seven subtypes in terms of specific gene fusions (ERG, ETV1/4, and FLI1) or mutations (SPOP, FOXA1, and IDH1) [2]. Local treatments refer to surgery and radiation therapy, while systemic treatments include hormonal therapy, targeted therapy, chemotherapy, and immunotherapy. Immunotherapies, such as immune checkpoint inhibitors (ICIs), have recently achieved success in treating various malignancies, including refractory and metastatic tumors [5]. Several ICIs, included sipuleucel-T [6], abiraterone acetate [7], enzalutamide [8], cabazitaxel [9], radium-223 [10], and apalutamide [11], have been approved by the Food and Drug Administration (FDA) to treat androgen depletion therapy-resistant PCs

Methods

Results

Conclusion